Medocriptine (Bromocriptine)

Bromocriptine, the active ingredient in Medocriptine, is an ergot derivative dopamine agonist presented as an oral tablet for oral use. It is prescribed to lower excess prolactin, improve motor symptoms in Parkinson’s disease, and reduce growth hormone secretion in acromegaly.

GNH USA supplies Medocriptine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Medocriptine, a dopamine agonist, is used in conditions where dopaminergic pathways are dysregulated.

- Hyperprolactinemia: reduces prolactin levels and restores normal menstrual cycles or lactation control. - Parkinson's disease: improves motor function and reduces rigidity and tremor. - Acromegaly: suppresses growth hormone secretion and helps control disease activity.

Bromocriptine may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: general tiredness or reduced energy.

Serious or Rare Side Effects: - Cardiac valvulopathy: potential valve fibrosis requiring monitoring. - Pulmonary fibrosis: rare scarring of lung tissue. - Severe hypotension: marked drop in blood pressure leading to fainting.

Before initiating bromocriptine therapy, several safety considerations should be reviewed.

- Cardiovascular assessment: evaluate for pre‑existing heart disease before initiating therapy. - Liver function: monitor hepatic enzymes in patients with liver impairment. - Pregnancy: avoid use unless benefits outweigh risks, as safety data are limited. - Concomitant medications: review drugs that may potentiate hypotension or interact with dopamine pathways. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Bromocriptine interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Ergotamine-containing drugs: combined use can cause severe vasospasm and ischemia. - Antihypertensive agents (e.g., alpha‑blockers): may produce additive hypotensive effects. - CYP3A4 inhibitors (e.g., ketoconazole): increase bromocriptine plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antipsychotics (e.g., haloperidol): may antagonize dopamine agonist action, reducing efficacy. - SSRIs or other serotonergic agents: potential for serotonin syndrome, monitor symptoms. - Oral contraceptives: bromocriptine may reduce estrogen levels, affecting contraceptive reliability.